PCP Prophylaxis in Patients with HIV and G6PD Deficiency

Introduction to PCP Prophylaxis

The US Public Health Service and Infectious Diseases Society of America recommend atovaquone as an alternative prophylactic agent for PCP when TMP-SMZ cannot be tolerated, especially in patients with a CD4 count of less than 100 cells/mm³ 1, 4, 5

Atovaquone is safe in G6PD deficiency, as it does not cause hemolysis in G6PD-deficient patients, making it a suitable alternative for PCP prophylaxis in this population 1, 4
Atovaquone appears to be as effective as aerosolized pentamidine or dapsone for PCP prophylaxis, according to guidelines from the USPHS/IDSA 1, 4

Dapsone is absolutely contraindicated in patients with G6PD deficiency due to the risk of hemolytic reactions, as recommended by the Annals of Oncology 2, 3
Primaquine is also contraindicated in G6PD deficiency due to hemolytic risk, making clindamycin-primaquine an unsuitable alternative for PCP treatment in this patient population 2, 3

Aerosolized pentamidine is less convenient, less effective than atovaquone for systemic prophylaxis, and does not provide cross-protection against toxoplasmosis, which may be necessary for patients with CD4 counts less than 100 cells/mm³ 4, 1, 5

The US Public Health Service and Infectious Diseases Society of America guidelines emphasize the importance of checking G6PD status before prescribing dapsone or primaquine to avoid life-threatening hemolysis 2, 3
Atovaquone is the safest option for PCP prophylaxis in patients with G6PD deficiency when TMP-SMZ fails, despite being more expensive, as recommended by the USPHS/IDSA 1, 4
Patients with CD4 counts less than 100 cells/mm³, like the one described, require continued PCP prophylaxis, and stopping prophylaxis is not an option, according to the USPHS/IDSA guidelines 1, 4, 5